28 results about "Cytisine" patented technology

The invention provides atomized liquid. The atomized liquid is prepared from nicotine, cytisine and a solvent. By using the cytisine which has a synergistic effect with the nicotine, on the premise that the dosage of the nicotine is not increased, the atomized liquid which is better in satisfaction and better in tobacco addiction relieving effect is provided.

The invention discloses an Escherichia coli mutant strain which is classified and named as Escherichia coli, the strain number is CR-TK01, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.35554. The invention further discloses a preparation method of the Escherichia coli mutant strain. The Escherichia coli CR-TK01 with high yield of cytidine provided by the invention has the characteristics of high yield and stable high-yield character, glucose is used as a carbon source, the Escherichia coli CR-TK01 is used for fermentation production of cytidine under a certain fermentation condition, and the yield of cytidine is as high as 97.23 g / L; the strain is not degraded after passage for more than 20 generations, the performance of high-yield cytidine is maintained in the passage fermentation process, and the yield of cytidine in passage fermentation is improved. The method for producing cytidine through fermentation is simple in process, high in yield and suitable for industrialization.

The invention discloses application of a cytisine type alkaloid and a derivative thereof in preparation of a medicine for preventing or treating respiratory syncytial virus infection, and relates to the technical field of respiratory syncytial virus prevention and treatment. The research finds that the natural product cytisine shows good anti-respiratory syncytial virus infection activity in vivo and in vitro, and finds that the cytisine can obviously relieve lung injury caused by virus infection and reduce lung inflammation; the invention provides an experimental basis for developing an efficient and safe drug for resisting respiratory syncytial virus (RSV) infection. As a natural product, the cytisine reduces the social burden caused by treatment of respiratory syncytial virus infection and reduces the treatment cost.

Embodiments of the present application provide an atomization liquid. The atomization liquid comprises: nicotine, cytisine and a solvent. By using cytisine that acts synergistically with nicotine, the atomization liquid that provides better satisfaction and has a better tobacco addiction relief effect is provided without increasing the dosage of nicotine.

Provided herein is a pharmaceutical composition comprising cytisine and a nitrite scavenger, wherein, upon storage of the composition at about 60 ºC, the amount of N-nitrosocytisine relative to a total weight of cytisine is 4.2 ng / mg or less after about 30 days. A method of manufacturing a cytisine tablet is also provided.

The present invention discloses the use of cytisine-N-methylene-(5,7,4'-trihydroxy) isoflavone in the preparation of a drug for treating cerebral infarction. The invention relates to the fields of medicine, natural products, traditional Chinese medicine, and functional foods. The compound has both alkaloid and isoflavone structures, a novel structure, and good drugability. It also contains both flavonoid and alkaloid structural characteristics and is combined with any excipient or carrier acceptable in pharmaceutical, nutritional, and food science. The compound of the present invention can be used as an active ingredient in the treatment of cerebral infarction, inhibiting ischemic brain damage. It not only has a significant therapeutic effect on cerebral infarction, but also possesses multi-level, multi-target comprehensive pharmacological effects and targeted treatment of various pathological mechanisms.

Provided herein is a pharmaceutical composition comprising cytisine and a nitrite scavenger, wherein, upon storage of the composition at about 60° C., the amount of N-nitrosocytisine relative to a total weight of cytisine is 4.2 ng / mg or less after about 30 days. A method of manufacturing a cytisine tablet is also provided.

Methods of assessing purity of cytisine using gradient chromatography at multiple wavelengths is provided herein.

The present invention relates to a stabilizing composition having significantly improved shelf stability. More specifically, the present invention relates to a stable liquid aqueous pharmaceutical composition comprising cytisine or a pharmaceutically acceptable salt thereof, at least one antioxidant selected from the group consisting of sulfite, bisulfite and pyrosulfite compounds. The invention also relates to the use of at least one antioxidant selected from the group consisting of sulfite, bisulfite and pyrosulfite compounds for the stabilization of a liquid aqueous pharmaceutical composition comprising cytisine.

A nicotine liquid preparation, and a preparation method therefor and the use thereof. The raw material components of the nicotine liquid preparation comprise nicotine, an additive capable of simulating the head-rush feeling of nicotine, an atomization solvent and an organic acid. The additive capable of simulating the head-rush feeling of nicotine is selected from at least one of cytisine, magnolol and 6-methylnicotine. The nicotine liquid preparation has a nicotine content of 10-20 mg / g.

The invention provides a green synthesis method of an alpha-aminoketone compound based on visible light catalytic oxidation amination reaction, and belongs to the technical field of organic chemical synthesizing.According to the method, aliphatic aldehyde and secondary amine which are low in price and easy to obtain serve as raw materials, oxygen serves as a green terminal oxidizing agent, and the alpha-aminoketone compound is synthesized under normal temperature and visible light irradiation. The alpha-aminoketone compound is efficiently synthesized in one step through oxidative amination reaction catalyzed by organic photosensitizers such as rhodamine 6G and anthraquinone. According to the method, a noble metal catalyst and a stoichiometric oxidant are abandoned, the reaction condition is mild (room temperature), the operation is simple and convenient, the substrate application range is wide, and the method shows excellent compatibility to functional groups including various complex cyclic secondary amines (such as natural product derivatives of nornicotine, cytisine and the like); compared with the prior art, the method has the advantages that important transformation from thermal activation to light activation is realized on the reaction mechanism, and a novel green way which is more economical and environment-friendly and is easy for large-scale production is provided for synthesis of alpha-aminoketone.

The present invention relates to a transdermal therapeutic system (TTS) for transdermal administration of cytisine, the transdermal therapeutic system comprising a self-adhesive layer structure comprising a therapeutically effective amount of cytisine, such cytisine TTS for use in a method of treatment and a method for making such cytisine TTS.

Methods for the treatment of addiction and / or dependence are provided, methods to promote the cessation of various addictions, such as smoking and / or vaping, and methods to promote a reduction of various addictions, such as smoking and / or vaping, uses of cytisine as a treatment to quit addiction and dosage regimens for the above.

The present application relates to the technical field of electronic atomization, and specifically relates to a nicotine replacement liquid preparation, and a preparation method therefor and the use thereof. In the nicotine replacement liquid preparation provided in the present application, the raw material components of the nicotine replacement liquid preparation comprise an additive capable of simulating the throat-hit sensation of nicotine, an additive capable of simulating the head-rush sensation of nicotine, and an atomization solvent. The additive capable of simulating the throat-hit sensation of nicotine is selected from at least one of piperine and 6-methylnicotine; and the additive capable of simulating the head-rush sensation of nicotine is selected from at least one of cytisine, magnolol and 6-methylnicotine. The nicotine replacement liquid preparation of the present application simulates the head-rush sensation and throat-hit sensation brought about by nicotine, enhances the head-rush sensation and throat-hit sensation of a nicotine-free atomization preparation, and improves the sense of satisfaction of a user, thereby achieving the aim of relieving addiction physiologically. Moreover, the toxicity and addictiveness of the nicotine replacement liquid preparation are both much lower than nicotine, such that damages to health can be reduced.

Salts of cytisine have been prepared and incorporated in stable pharmaceutical compositions, including compositions comprising lactose. The salts are prepared by adding acid stock solutions to solutions of cytisine with heating, followed by cooling to ambient temperature. The salts and compositions are indicated in the treatment of nicotine addiction.

The present invention relates to a liquid pharmaceutical composition comprising cytisine, at least one inorganic pH regulator selected from the group consisting of inorganic acids, inorganic buffers, and salts of inorganic acids, and water, wherein the liquid pharmaceutical composition has a pH value between 3.0 and 7.5. The present invention also relates to the liquid pharmaceutical composition for use in the treatment of tobacco addiction and other forms of nicotine addiction. Additionally, the invention relates to a liquid pharmaceutical composition comprising cytisine for oral use in the treatment of tobacco addiction and other forms of nicotine addiction.

The invention provides a novel application of cytisine, and belongs to the field of medicines. The invention provides application of cytisine in preparation of a medicine for treating pulmonary heart disease. Compared with the cytisine, the cytisine-polypeptide coupling compound (PDC medicine) prepared by coupling the cytisine and the polypeptide has the advantages that the dosage is obviously reduced, the effect is better, the right heart dysfunction can be improved, the myocardial fibrosis is reduced, the right heart remodeling is alleviated, and a new choice is provided for clinically treating the pulmonary heart disease.

A unit dosage comprising a succinate salt of cytisine formulated as a pharmaceutical composition further comprising a pharmaceutically acceptable excipient, and use in treating a nicotine addiction.

The invention relates to the technical field of electronic atomization, in particular to a nicotine substitute liquid preparation and a preparation method and application thereof. The invention provides a nicotine substitution liquid preparation. The nicotine substitution liquid preparation comprises the following raw material components: a nicotine throat hitting feeling simulation additive, a nicotine head feeling simulation additive and an atomization solvent, the nicotine throat hitting feeling simulation additive is selected from at least one of piperine and 6-methyl nicotine; the nicotine head feeling simulation additive is selected from at least one of cytisine, magnolol and 6-methyl nicotine. The nicotine replaces a liquid preparation to simulate the feeling of feeling on the head and the feeling of hitting the throat caused by the nicotine, the feeling of feeling on the head and the feeling of hitting the throat of the nicotine-free atomized preparation are improved, the satisfaction of a user is improved, the aim of physiologically relieving addiction is achieved, meanwhile, the toxicity and addiction of the nicotine-free atomized preparation are far lower than those of the nicotine, and health damage can be reduced.

The invention relates to the technical field of electronic atomization, in particular to a nicotine liquid preparation and a preparation method and application thereof. The nicotine liquid preparation provided by the invention is prepared from the following raw material components: nicotine, a nicotine head feeling simulation additive, an atomizing solvent and organic acid, the nicotine head feeling simulation additive is selected from at least one of cytisine, magnolol and 6-methyl nicotine; the content of nicotine in the nicotine liquid preparation is 10-20 mg / g. According to the nicotine liquid preparation formed by compounding the head feeling simulation additive and the nicotine on the specific nicotine, under the synergistic effect of all the components, the satisfaction of a user on the low-nicotine-content liquid preparation is improved, and under the condition of the same experience feeling, the toxicity and addiction are reduced, and health damage is reduced.

The application provides an antitumor delphinine alkaloid in Caesalpinia minax, a core skeleton of angustifoline type, and provides an extraction method and application, and compound 3 is used for preparation of an antitumor drug. The natural delphinine with a new angustifoline type structural skeleton is obtained by separation and extraction, wherein compound 3 has a significant inhibitory effect on multiple tumor cell strains, and can be used for preparation of an antitumor drug.

Provided herein is an oral pharmaceutical composition that contains a cholinergic agent, a natural plant alkaloid in particular, selected from the group of lobeline, anabasine, cytisine, galantamine or acceptable salts thereof, in the form of tablets and capsules. The oral pharmaceutical composition is applicable in the treatment of dependency and addiction to nicotine, tobacco products, and alcohol.

Provided herein is a cytisine formulation comprising cytisine, a nitrite scavenger, a glidant, a lubricant, a buffering agent and one or more fillers, wherein, upon storage of the composition at about 60 ºC, the amount of N-nitrosocytisine relative to a total weight of cytisine is 4.2 ng / mg or less after about 30 days.

Provided herein is a cytisine formulation comprising cytisine, a nitrite scavenger, a glidant, a lubricant, a buffering agent and one or more fillers, wherein, upon storage of the composition at about 60° C., the amount of N-nitrosocytisine relative to a total weight of cytisine is 4.2 ng / mg or less after about 30 days.